IBM study, with funding from Myositis UK

IBM study, with funding from Myositis UK:

In this exploratory study, comparison of patients with IBM with and without anti-cN-1A autoantibody reactivity identified differences in their mortality risk, clinical characteristics and histopathological findings. The largest study of its kind has demonstrated that anti-cN-1A antibody testing may, and over and above its diagnostic value, be clinically useful to define distinct IBM subtypes.

1 Reply

  • Sounds interesting

You may also like...